# US 2022/0033476 A1 · Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033476 A1
- Document ID: US20220033476A1
- Status: Published application
- Kind: A1
- Application number: 17/280,343
- Filed: 2019-09-24
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: Ampsource Biopharma Shanghai Inc.; Pharmab, Inc.
- Applicants: Ampsource Biopharma Shanghai Inc.; Pharmab, Inc.
- Inventors: Yongjuan Gao; Shixiang Jia; Yuncheng Zheng; Yingying Jin; Zhu Wang; Zhao Dong; Si Chen; Bill Nai-chau Sun; Qiang Li
- Web page: https://patentgrep.com/patent/US20220033476A1

## CPC

- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- A61K 38/37: Factors VIII
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/91: containing a motif for glycosylation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-domain, a flexible peptide linker, at least one rigid unit of a carboxyl-terminal peptide of a human chorionic gonadotropin beta subunit, and a half-life prolonging moiety (preferably an IgG Fc variant). The fusion protein has a similar biological activity to a recombinant FVIII, a prolonged active half life in vivo, and better stability in vitro and in vivo, and thus improves the pharmacokinetics and efficacy of the fusion protein.

## Claims

### Claim 1

A fusion protein of human coagulation factor VIII, comprising sequentially from the N-terminus to the C-terminus a mutant single-chain human coagulation factor VIII with a partially deleted B domain, a flexible peptide linker, at least one carboxyl-terminal peptide rigid unit of human chorionic gonadotropin β-subunit, and a half-life extending moiety; wherein the single-chain human coagulation factor VIII has an amino acid sequence as shown in SEQ ID NO: 2, and the half-life extending moiety is selected from an immunoglobulin Fc fragment, albumin, transferrin, or PEG.

### Claim 2 (depends on 1)

The fusion protein according to claim 1, wherein the fusion protein is glycosylated by being expressed in Chinese hamster ovary cells.

### Claim 3 (depends on 1)

The fusion protein according to claim 1, wherein the mutant single-chain human coagulation factor VIII with a partially deleted B domain comprises an amino acid sequence as shown in SEQ ID NO: 2, or the single-chain human coagulation factor VIII has an amino acid sequence that shares at least 90% identity to the amino acid sequence as shown in SEQ ID NO: 2.

### Claim 4 (depends on 1)

The fusion protein according to claim 1, wherein the flexible peptide linker contains two or more amino acids selected from G, S, A, and T residues;
wherein, the flexible peptide linker has an amino acid sequence general formula formed by combining cyclic unit (GS)a(GGS)b(GGGS)c(GGGGS)d, wherein a, b, c, and d are integers greater than or equal to 0 and a+b+c+d≥1.

### Claim 5 (depends on 1)

The fusion protein according to claim 1, wherein the carboxyl-terminal peptide rigid unit of human chorionic gonadotropin β-subunit comprises an amino acid sequence as shown in SEQ ID NO: 3 or a truncated sequence thereof, wherein the truncated sequence comprises at least two glycosylation sites.

### Claim 6 (depends on 1)

The fusion protein according to claim 1, wherein the carboxyl-terminal peptide rigid unit of human chorionic gonadotropin β-subunit shares at least 70%, 80%, 90%, or 95% identity to an amino acid sequence as shown in SEQ ID NO: 3, or to a following amino acid sequence:
(SEQ ID NO: 3)
(i)
PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(SEQ ID NO: 12)
(ii)
SSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(SEQ ID NO: 13)
(iii)
SSSSKAPPPS;
or
(SEQ ID NO: 14)
(iv)
SRLPGPSDTPILPQ.

### Claim 7 (depends on 1)

The fusion protein according to claim 1, wherein the fusion protein comprises 1, 2, 3, 4, or 5 carboxyl-terminal peptide rigid units of human chorionic gonadotropin β-subunit.

### Claim 8 (depends on 1)

The fusion protein according to claim 1, wherein the half-life extending moiety is a human IgG Fc variant having a reduced ADCC effect and/or CDC effect and/or enhanced binding affinity with an FcRn receptor.

### Claim 9 (depends on 1)

The fusion protein according to claim 1, wherein the fusion protein has an amino acid sequence as shown in SEQ ID NO: 9.

### Claim 10 (depends on 1)

The fusion protein according to claim 1, wherein the fusion protein has activity of greater than 6000 IU/mg.

### Claim 11 (depends on 1)

DNA for encoding the fusion protein according to claim 1.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier, excipient, or diluent and an effective dose of the fusion protein according to claim 1.

### Claim 15 (depends on 1)

A method for preparing the fusion protein according to claim 1, comprising:
(a) introducing the DNA sequence for encoding the fusion protein into a CHO cell to produce a CHO-derived cell line;
(b) screening in step (a) a high-yielding cell strain that expresses more than 1 IU/106 (million) cells every 24 hours in a growth medium thereof;
(c) culturing the cell strain screened in step (b) to express the fusion protein;
(d) harvesting a fermentation broth obtained in step (c) and separating and purifying the fusion protein.

### Claim 16 (depends on 15)

The method according to claim 15, wherein a purification process of the fusion protein in step (d) comprises affinity chromatography, hydrophobic chromatography, anion exchange chromatography, and molecular sieve chromatography.

### Claim 17 (depends on 1)

A method for prevention or treatment of a hemorrhagic disease in a patient with a congenital or acquired FVIII deficiency, or spontaneous or surgical bleeding in a patient with hemophilia A, comprising administrating the fusion protein of claim 1 to a patient.

### Claim 18 (depends on 1)

The fusion protein according to claim 1, wherein the flexible peptide linker is any one selected from the following group consisting of:
(SEQ ID NO: 15)
(i)
GSGGGSGGGGSGGGGS;
(SEQ ID NO: 16)
(ii)
GSGGGGSGGGGSGGGGSGGGGSGGGGS;
(SEQ ID NO: 17)
(iii)
GGGGSGGGGSGGGGSGGGGS;
(SEQ ID NO: 18)
(iv)
GSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS;
and
(SEQ ID NO: 19)
(v)
GGGSGGGSGGGSGGGSGGGS.

### Claim 19 (depends on 1)

The fusion protein according to claim 1, wherein the carboxyl-terminal peptide rigid unit of human chorionic gonadotropin β-subunit comprises an amino acid sequence selected from the following group consisting of:
(SEQ ID NO: 13)
(i)
PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(SEQ ID NO: 12)
(ii)
SSSSKAPPPSLPSPSRLPGPSDTPILPQ;
(SEQ ID NO: 13)
(iii)
SSSSKAPPPS;
and
(SEQ ID NO: 14)
(iv)
SRLPGPSDTPILPQ.

### Claim 20 (depends on 8)

The fusion protein according to claim 8, wherein the Fc variant is any one selected from the following group consisting of:
(i) human IgG1 hinge region, CH2 region, and CH3 region containing Leu234Val, Leu235Ala, and Pro331 Ser mutations;
(ii) human IgG2 hinge region, CH2 region, and CH3 region containing Pro331 Ser mutation;
(iii) human IgG2 hinge region, CH2 region, and CH3 region containing Thr250Gln and Met428Leu mutations;
(iv) human IgG2 hinge region, CH2 region, and CH3 region containing Pro331Ser, Thr250Gln, and Met428Leu mutations; and
(v) human IgG4 hinge region, CH2 region, and CH3 region containing Ser228Pro and Leu235Ala mutations.

### Claim 21 (depends on 11)

The DNA according to claim 11, which has a sequence as shown in SEQ ID NO: 10.
